LTGO insider buying and SEC filings, explained
Latigo Biotherapeutics, Inc. · CIK 2056611
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$5.0M
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 10, 2026 | Purchase (code P) | James B. Tananbaum (Director and 10% owner) bought 140,000 shares indirectly at $18.00 ($2.5M), reported as a purchase (code P). Indirect holdings up 7% to 2,008,024 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 10, 2026 |
| Aug 10, 2026 | Purchase (code P) | Foresite Capital Fund V, L.P. (10% owner) bought 140,000 shares indirectly at $18.00 ($2.5M), reported as a purchase (code P). Indirect holdings up 7% to 2,008,024 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 5 other reporting owners. | SEC filing Filed Aug 10, 2026 |
7 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$5.0M in purchases since Aug 10, 2026 · Purchases traded Aug 10, 2026 to Aug 10, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Foresite Capital Fund V, L.P. (10% owner) | $2.5M | Aug 10, 2026 | SEC filing |
| James B. Tananbaum (Director) | $2.5M | Aug 10, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow LTGO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.